Astellas, Ambit announce outcomes from quizartinib Phase 2 research on acute myeloid leukemia Astellas Pharma Inc. and Ambit Biosciences Company announced today that the outcomes from a completed Stage 2 study with the investigational FLT3 inhibitor, quizartinib , as an oral monotherapy treatment program in patients with relapsed or refractory severe myeloid leukemia were presented at the 54th Annual Meeting of the American Society of Hematology . The Phase 2 ACE research recruited sufferers into two distinct cohorts of patients with relapsed/refractory AML, and the results from each cohort of had been presented in specific oral sessions read .e.
Astellas, AVEO enter development, commercialization agreement for tivozanib Astellas Pharma Inc. , a worldwide pharmaceutical firm, and AVEO Pharmaceuticals, Inc. today announced they have entered into a worldwide agreement outside of Asia to build up and commercialize tivozanib, AVEO’s lead product applicant made to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treating a broad selection of cancers. AVEO can be eligible to receive around $1. At the mercy of regulatory authorization, AVEO will business lead commercialization of tivozanib in THE UNITED STATES and Astellas will business lead commercialization of tivozanib in europe . The firms will share equally all North EU and American development and commercialization costs and profits for tivozanib.